Cancer BiologyBlood NeoplasiaPeer-reviewed
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS
H. Josh Jang, Guillermo Urrutia, Andreas Due Ørskov…·Peter A. Jones
The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.
1 citation